Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Citi
Boehringer Ingelheim
McKesson
Express Scripts
Accenture
Deloitte
AstraZeneca
UBS
Queensland Health

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,178,554

« Back to Dashboard

Which drugs does patent 8,178,554 protect, and when does it expire?

Patent 8,178,554 protects AVYCAZ and is included in one NDA.

This patent has fifty-three patent family members in forty-two countries.
Summary for Patent: 8,178,554
Title:Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: ##STR00001## The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
Inventor(s): Lampilas; Maxime (Romainville, FR), Aszodi; Jozsef (Tucson, AZ), Rowlands; David Alan (Poissy, FR), Fromentin; Claude (Paris, FR)
Assignee:
Application Number:13/068,399
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,178,554

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc AVYCAZ avibactam sodium; ceftazidime POWDER;IV (INFUSION) 206494-001 Feb 25, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,178,554

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 10121Aug 1, 2000

Non-Orange Book US Patents Family Members for Patent 8,178,554

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,112,592 Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents ➤ Sign Up
7,638,529 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents ➤ Sign Up
7,732,610 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,178,554

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1468242 ➤ Sign Up
China 1289500 ➤ Sign Up
Costa Rica 6895 ➤ Sign Up
African Regional IP Organization (ARIPO) 1614 ➤ Sign Up
Argentina 031716 ➤ Sign Up
Czech Republic 20030223 ➤ Sign Up
Czech Republic 294956 ➤ Sign Up
Germany 60102702 ➤ Sign Up
Denmark 1307457 ➤ Sign Up
Algeria 3397 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Baxter
Chinese Patent Office
UBS
US Department of Justice
Mallinckrodt
McKesson
Chubb
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot